204512-13-0Relevant articles and documents
1,2,4-Triazolo[4,3-a]quinoxalin-1-one moiety as an attractive scaffold to develop new potent and selective human A3 adenosine receptor antagonists: Synthesis, pharmacological, and ligand-receptor modeling studies
Colotta, Vittoria,Catarzi, Daniela,Varano, Flavia,Calabri, Francesca Romana,Lenzi, Ombretta,Filacchioni, Guido,Martini, Claudia,Trincavelli, Letizia,Deflorian, Francesca,Moro, Stefano
, p. 3580 - 3590 (2004)
In the past few years much effort in our laboratory has been directed toward the study of adenosine receptor antagonists, and recently we focused our attention on 2-aryl-1,2,4-triazolo[4,3-a]quinoxaline-1,4-diones and 2- aryl-1,2,4-triazolo[4,3-a]quinoxal
Tricyclic heteroaromatic systems. 1,2,4-Triazolo[4,3-a]quinoxalines and 1,2,4-triazino[4,3-a]quinoxalines: Synthesis and central benzodiazepine receptor activity
Colotta, Vittoria,Catarzi, Daniela,Varano, Flavia,Cecchi, Lucia,Filacchioni, Guido,Galli, Alessandro,Costagli, Chiara
, p. 387 - 391 (2007/10/03)
Some 1,2,4-triazolo[4,3-a]quinoxalines 1-10, and 1,2,4-triazino[4,3-a]quinoxalines 11-12 were prepared and biologically evaluated for their binding at the benzodiazepine receptor (BZR) in rat cortical membranes. The BZR affinity of 1-10 demonstrates that